/GRI
GRI Stock - GRI Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.34-8.03%
$0.03 (-8.03%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.37
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GRI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.34 – $0.34
TARGET (TP)$0.39
STOP LOSS$0.31
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.58
52W High$15.64
52W Low$0.33
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-4,000 | $-57,000 | $-50,000 | $-73,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,234,999 | $-11,387,000 | $-2,239,000 | $-9,259,000 | $-1,459,000 |
| Net Income | $-8,207,000 | $-13,037,000 | $-3,217,000 | $-9,303,000 | $-2,531,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-55.21 | $-6242.18 | $-165346.00 | $-815.80 | $-32856.00 |
Company Overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 2841.2% Upside
Now
$10
Low
$10
Average
$10
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2024 | H.C. Wainwright | Initiation | Buy | $10 |
Earnings History & Surprises
GRIBeat Rate
33%
Last 9 quarters
Avg Surprise
-153.8%
EPS vs Estimate
Beats / Misses
3/6
Last 12 quarters
Latest EPS
$-1.28
Q4 2025
EPS Surprise History
Q2 24
No data
Q3 24
No data
Q3 24
No data
Q4 24
-1460.3%
$-11.39vs$-0.73
Q2 25
-41.1%
$-5.80vs$-4.11
Q3 25
No data
Q3 25
-18.2%
$-1.31vs$-1.11
Q4 25
-15.3%
$-1.28vs$-1.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 13, 2026 | $-1.13 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.11 | $-1.28 | -15.3% | ✗ MISS |
Q3 2025 | Aug 18, 2025 | $-1.11 | $-1.31 | -18.2% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | — | $-5.80 | — | — |
Q2 2025 | May 15, 2025 | $-4.11 | $-5.80 | -41.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.73 | $-11.39 | -1460.3% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | — | $-83.67 | — | — |
Q3 2024 | Jul 31, 2024 | — | $-5.94 | — | — |
Q2 2024 | May 10, 2024 | — | $-101.73 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-4317.86 | — | — |
Q2 2023 | May 15, 2023 | — | $-8248.81 | — | — |
Q1 2023 | Feb 24, 2023 | $-13458.90 | $-0.10 | +100.0% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-11602.50 | $-32.05 | +99.7% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-10674.30 | $-23.30 | +99.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-46.20 | $-55.74 | -20.7% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-46.20 | $-105.59 | -128.5% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-124.06 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-50.37 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-92.65 | — | — |
Latest News
GRI Bio Prices $8M Public Offering Of ~10.67M Shares And Series F Warrants At A Combined Price Of $0.75, To Fund Pipeline Development
➖ NeutralBenzinga•Dec 11, 2025, 02:19 PM
GRI stock has given up its prior gain. GRI Bio shares were trading higher after the company announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis met its primary and secondary endpoints.
➖ NeutralBenzinga•Dec 10, 2025, 10:10 PM
UPDATE: GRI Bio's GRI-0621 Meets Primary And Secondary Endpoints In Phase 2a IPF Trial, Showing Strong Safety, Biomarker Improvements And Increased FVC
📈 PositiveBenzinga•Dec 10, 2025, 09:30 PM
GRI Bio shares are trading higher after the company announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis met its primary and secondary endpoints.
📈 PositiveBenzinga•Dec 10, 2025, 09:29 PM
GRI Bio Announces Phase 2a GRI-0621 Study In Idiopathic Pulmonary Fibrosis Met Primary Endpoint
📈 PositiveBenzinga•Dec 10, 2025, 09:13 PM
Gri Bio Phase 2a Trial For Idiopathic Pulmonary Fibrosis Met Primary Endpoint & Certain Secondary Endpoints
📈 PositiveBenzinga•Dec 8, 2025, 01:15 PM
GRI Bio's GRI-0621 Meets Primary Endpoint In Phase 2a IPF Trial, Showing Improved FVC, Biomarker Evidence Of Anti-Fibrotic Activity And Strong Safety Profile
📈 PositiveBenzinga•Dec 8, 2025, 01:14 PM
Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $36
📈 PositiveBenzinga•Dec 8, 2025, 10:25 AM
GRI Bio Q3 EPS $(1.28) Misses $(0.93) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 02:28 PM
Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $35
📈 PositiveBenzinga•Sep 22, 2025, 09:50 AM
GRI Bio shares are trading higher after the company announced interim 6-week lung function results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.
📈 PositiveBenzinga•Sep 11, 2025, 01:06 PM
GRI Bio Reports Interim 6-Week Lung Function Results From Ongoing Phase 2a Study Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis; Phase 2a Study Fully Enrolled; Topline Data On Track For Q3 2025
➖ NeutralBenzinga•Sep 11, 2025, 12:47 PM
Frequently Asked Questions about GRI
What is GRI's current stock price?
GRI Bio, Inc. (GRI) is currently trading at $0.34 per share. The stock has moved -8.03% today.
What is the analyst price target for GRI?
No analyst price targets are currently available for this stock.
What sector is GRI Bio, Inc. in?
GRI Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GRI's market cap?
GRI Bio, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does GRI pay dividends?
No, GRI Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABP
Abpro Corporation
$5.06
Mkt Cap: $0.0B
BDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CLDI
Calidi Biotherapeutics, Inc.
$1.36
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GNPX
Genprex, Inc.
$2.13
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SXTP
60 Degrees Pharmaceuticals, Inc.
$0.76
Mkt Cap: $0.0B
Explore stocks similar to GRI for comparison